Press Release
Kuala Lumpur, Malaysia – 26 February 2025 – Gene Solutions Malaysia is pleased to participate in the World Cancer Day 2025 launch, and enhance public knowledge of cancer prevention and treatment, officiated by the Ministry of Health Malaysia Ministry Of Health, Malaysia (KKM) and National Cancer Society Malaysia (NCSM) on February 26, 2025.
The Challenge we face
Cancer incidence in Malaysia continues to rise despite advancements in cancer management. Cancer remains a leading cause of death, accounting for 26.44% of deaths in private hospitals and ranking as the fourth leading cause of death in government hospitals (9.3%) (1).
According to the Malaysian Cancer Registry Report (2017-2021), the three most common cancers—breast, colorectal, and lung cancer—account for 41.8% of all cases. Alarmingly, a significant majority of lung cancer cases (76% of men and 94% of women) are diagnosed at advanced stages (Stage 3/4) (2). Late-stage diagnosis severely limits treatment options and drastically reduces survival rates.
One of the actions changing this trend lies in early-stage cancer detection, which increases survival rates, improves quality of life, and significantly reduces the financial burden on patients and their families.
Advancing the Early Action We can Take
Under the theme “United by Unique”, World Cancer Day 2025 emphasizes a patient-centered approach to cancer care. As part of this initiative, Gene Solutions Malaysia proudly presented SPOT-MAS, a clinical validated and non-invasive blood test that detects circulating tumor DNA (ctDNA) for early cancer screening.
Utilizing Next-generation sequencing and AI technologies, SPOT-MAS demonstrated high accuracy and efficiency in detecting 10 common types of cancers including those that currently lacking screening methods.
In a separate discussion, Kol. Bersekutu (PA) Assoc. Prof. Dr. Murallitharan Munisamy, Managing Director of NCSM, highlighted the significance of SPOT-MAS, stating:
“Early detection is crucial in the fight against cancer, and by welcoming technology that makes it more accessible, we open the door to earlier diagnoses, better outcomes, and a brighter future for all”
Breakthrough in Lung Cancer Detection
Besides detecting multiple cancers, Gene Solutions has also developed SPOT-MAS Lung, a specialized screening test for lung cancer. This test demonstrates a remarkable 90% sensitivity and 92% specificity and supplements as an essential companion to low-dose CT scans— assisting clinicians in cases where imaging results are inconclusive or when a person is not applicable for CT scans.
Gene Solutions commits to making personalized cancer care a reality through our specific technological and strategic approaches.
“We believe in our technology and vision of SPOT-MAS into improving early cancer detection chance. The test is now available in selected hospitals, clinics and here at NCSM to support current cancer screening efforts.”said Mr. Lim Chiun Khee, Country Director of Gene Solutions Malaysia.
We extend our gratitude to all who joined us in championing this cause at Malaysia’s World Cancer Day 2025 Launch. Together, we can drive progress in early detection and improve cancer outcomes nationwide.
➡️ For more information about early detection screening options available for you and your family, please visit our website: https://genesolutions.com/our-test/spot-mas
References:
- (1) According to the Department of Statistics Malaysia (DOSM) 2023 report
- (2) According to https://nci.moh.gov.my/images/pdf_folder/SUMMARY-OF-MALAYSIA-NATIONAL-CANCER-REGISTRY-REPORT-2017-2021.pdf
